Immuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Immuneering Corporation (NASDAQ:IMRX) has been given an average recommendation of "Moderate Buy" by analysts, with one analyst rating it a sell and four issuing buy ratings.
• The company's price target among brokerages has risen, with Mizuho setting it at $10.00, Oppenheimer at $30.00, and Needham at $11.00.
• Immuneering's stock has shown significant growth potential, with a 1-year low of $1.10 and a high of $10.08, while possessing a market capitalization of $335.89 million.

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has received an average recommendation of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $17.75.

Several research firms have weighed in on IMRX. Mizuho boosted their price target on Immuneering from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Wednesday, June 18th. Oppenheimer boosted their price target on Immuneering from $21.00 to $30.00 and gave the company an "outperform" rating in a research note on Thursday. Needham & Company LLC boosted their price target on Immuneering from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Monday, September 15th. Finally, Chardan Capital boosted their price target on Immuneering from $13.00 to $20.00 and gave the company a "buy" rating in a research note on Friday.

Institutional Trading of Immuneering

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC purchased a new stake in Immuneering in the 2nd quarter worth approximately $215,000. Bridgeway Capital Management LLC grew its stake in shares of Immuneering by 57.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company's stock worth $322,000 after purchasing an additional 35,000 shares during the period. XTX Topco Ltd purchased a new position in Immuneering in the second quarter valued at $90,000. Kingsview Wealth Management LLC acquired a new position in shares of Immuneering in the second quarter worth about $47,000. Finally, Geode Capital Management LLC boosted its stake in shares of Immuneering by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company's stock worth $776,000 after acquiring an additional 4,458 shares in the last quarter. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Price Performance

Shares of NASDAQ:IMRX opened at $8.08 on Monday. The business's 50-day moving average is $5.43 and its 200 day moving average is $3.23. Immuneering has a 1 year low of $1.10 and a 1 year high of $10.08. The firm has a market capitalization of $335.89 million, a P/E ratio of -4.28 and a beta of 0.43.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40). On average, analysts expect that Immuneering will post -1.86 EPS for the current year.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.